Enfusion (ENFN) reported Q3 adjusted net income Monday of $0.05 per diluted share, up from $0.04 a year earlier.
Analysts polled by Capital IQ expected $0.06.
Revenue for the quarter ended Sept. 30 was $51.2 million, up from $44.4 million a year earlier.
Analysts surveyed by Capital IQ expected $52.2 million.
For 2024, the company narrowed its revenue projection to between $202 million and $205 million, from a previous outlook of $200 million to $210 million. Analysts polled by Capital IQ expect $204.8 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。